Human beings tend to possess a lot of valuable traits, and yet the greatest trait they have ever possessed is the one that pushes them to get better on a consistent basis. This ability, in particular, has already allowed us to hit upon some huge milestones, with technology appearing as a major part of the stated group. The reason why technology gets to be such a notable part of our lives is largely predicated upon its unprecedented skill-set, which introduced us to all those possibilities that we could have never imagined otherwise. Beyond that, however, the whole runner was also inspired by how we applied the stated skills in the real-world setting. The latter component was, in fact, what gave the creation a spectrum-wide presence, including a very-well timed appearance on our healthcare block. Technology’s foray into healthcare was so perfectly timed because it came right when the sector was starting to struggle against its own obsolete structure. This reality was, of course, revamped under the new regime, but even after going so far, the medtech concept will continue to produce the goods. The same has become more and more evident over the recent, and it should only get a lot stronger on the back an FDA decision.
Anthos Therapeutics, a biotechnology company based in Cambridge, Massachusetts, has successfully landed FDA’s Fast Track designation for its monoclonal antibody, abelacimab. Designed to prevent stroke and systemic embolism in patients with atrial fibrillation, abelacimab works by inhibiting Factor XI. This enables the drug in regards to blocking the development of abnormal blood clots without affecting the process of generating normal blood clots that are required for blood to set. Interestingly enough, it’s the second Fast Track designation abelacimab has received in less than two months, as back in July, it realized a similar status for treating cancer-associated thrombosis (CAT).
“Factor XI inhibitors have the potential to uncouple the processes that lead to thrombosis from those that are involved in creating normal clots. By doing so, the hope is that this new class of anticoagulants will be at least as effective as current treatments – and have an enhanced safety profile. An alternative administration method and less frequent dosing will facilitate the care of patients who, for a variety of reasons, struggle with daily pill taking,” said Peter Kowey, professor of Medicine and Clinical Pharmacology at Sidney Kimmel Medical College at Thomas Jefferson University.
At the moment, abelacimab is in a Phase 2 study. The trial is understood to have around 1,287 patients, who hail from a total of 95 global study sites. The drug in question here also became the first ever Factor XI inhibitor to start enrolling patients in Phase 3 trials. For this one, though, Anthos plans to enlist 2,700 patients from over 220 sites.